Roivant Sciences (ROIV) Net Income towards Common Stockholders (2020 - 2024)
Roivant Sciences (ROIV) reported Net Income towards Common Stockholders of $327.0 million for Q4 2024, up 661.1% on a YoY basis from $43.0 million in Q1 2024, and up 859.05% quarter-over-quarter from -$43.1 million in Q3 2024.
Roivant Sciences (ROIV) Net Income towards Common Stockholders (2020 - 2024) Analysis & Trends
Roivant Sciences has reported Net Income towards Common Stockholders for 5 years, with the latest figure at $327.0 million in Q4 2024.
- For the quarter ending Q4 2024, Net Income towards Common Stockholders rose 661.1% year-over-year to $327.0 million; the trailing twelve-month figure through Sep 2025 stood at $327.0 million (up 2764.77% YoY), and the FY2025 full-year result was $373.2 million, up 218.93% from the prior year.
- Net Income towards Common Stockholders for Q4 2024 stood at $327.0 million, up from -$43.1 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $327.0 million in Q4 2024, with the low at -$384.9 million in Q4 2022.
- Historically, Net Income towards Common Stockholders has averaged -$141.6 million across 5 years, with a median of -$101.1 million in 2021.
- Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders tumbled 1167.12% — and 2024, when it jumped 661.1%.
- Roivant Sciences' Net Income towards Common Stockholders stood at -$275.6 million in 2020, then slipped by 11.06% to -$306.1 million in 2021, then decreased by 25.75% to -$384.9 million in 2022, then jumped by 84.86% to -$58.3 million in 2023, then jumped by 661.1% to $327.0 million in 2024.
- The last three Net Income towards Common Stockholders figures came in at $327.0 million (Q4 2024), -$43.1 million (Q3 2024), and $89.1 million (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Roivant Sciences | 21.82 Bn | 22.59 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 327.02 Mn |
| Sep 30, 2024 | -43.08 Mn |
| Jun 30, 2024 | 89.09 Mn |
| Dec 31, 2023 | -58.28 Mn |
| Sep 30, 2023 | -86.48 Mn |
| Jun 30, 2023 | -327.85 Mn |
| Dec 31, 2022 | -384.90 Mn |
| Sep 30, 2022 | -315.92 Mn |
| Jun 30, 2022 | -353.78 Mn |
| Dec 31, 2021 | -306.09 Mn |
| Sep 30, 2021 | -225.64 Mn |
| Jun 30, 2021 | -101.08 Mn |
| Dec 31, 2020 | -275.60 Mn |
| Sep 30, 2020 | -53.50 Mn |
| Jun 30, 2020 | -7.98 Mn |